Hiroaki Mitsuya

Hiroaki Mitsuya (満屋 裕明, Mitsuya Hiroaki, born 1950) is a Japanese virologist famous for his role in discovery of the anti-HIV drug zidovudine (AZT) as well as other anti-AIDS drugs including didanosine (ddI) and zalcitabine (ddC).

Mitsuya was born in Sasebo, Nagasaki and received his M.D. and Ph.D. from Kumamoto University. He joined the American National Cancer Institute in Bethesda, Maryland, in 1982, working initially on Human T-lymphotropic virus 1 before switching his attention to HIV. His identification of AZT as an anti-HIV drug, as well as the anti-HIV properties of didanosine and zalcitabine, was made in 1985. He was appointed Professor of Hematology, Rheumatology and Clinical Immunology at Kumamoto University Graduate School of Medical And Pharmaceutical Sciences.

In December, 2006, he was awarded the first NIH World AIDS Day Award for his work in developing drugs for AIDS. Mitsuya has been chief of the NCI's Experimental Retrovirology Section since 1991.

gollark: Oh yes, and Apple progressively removing APIs they don't like because vendor lock in is bad.
gollark: <@550187576049270798> Yes, `brew` which is unofficial and so runs on top of the existing system, which isn't ideal, and the app store which doesn't really count.
gollark: <@550187576049270798> Desktop Linux is usable. Linux distros are generally way more customizable, run better without £1000 hardware, actually have package managers, and don't have all the Apple app store stuff going on.
gollark: Also odd CPU choice.
gollark: Odd hostname.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.